T-cell immunoglobulin mucin-3 expression in invasive ductal breast carcinoma: Clinicopathological correlations and association with tumor infiltration by cytotoxic lymphocytes
Authors:
Open Access
- 3 August 2017
- journal article
- research article
- Published by Spandidos Publications in Molecular and Clinical Oncology
- Vol. 7 (4) , 557-563
Abstract
As a negative regulatory molecule, T-cell immunoglobulin and mucin domain-3 (Tim-3) is closely associated with tumor immunological tolerance. The aim of this study was to investigate Tim‑3 expression in invasive ductal breast cancer (IDC), its effect on clinicopathological parameters and its association with cytotoxic lymphocyte infiltration. Tim‑3 protein expression was measured in 150 paraffin‑embedded IDC specimens and 100 paired normal breast tissue specimens by immunohistochemistry. It was demonstrated that the infiltration of the tumor by CD8+ T cells was significantly higher compared with that of normal tissue, and the Tim‑3 expression on CD8+ T cells was higher in IDC tissue compared with that in normal tissue; the differences were statistically significant (both P‑values=0.000). The median expression level of Tim‑3 on tumor cells was significantly associated with clinicopathological parameters such as age, axillary lymph node metastasis and TNM stage (P=0.015, 0.001 and 0.027, respectively). The expression of Tim‑3 on CD8+ T cells was correlated with lymph node metastasis, World Health Organization (WHO) grade and molecular classification (P=0.000, 0.004 and 0.000, respectively). Additionally, the number of tumor‑infiltrating CD8+ T cells was associated with primary tumor size, lymph node metastasis, WHO grade, Ki‑67 and molecular classification (P=0.017, 0.002, 0.007, 0.003 and 0.000, respectively). Thus, Tim‑3 may promote the development and progression of breast cancer and affect the tumor microenvironment; thus, it may be used as an independent prognostic factor for IDC patients.Keywords
This publication has 28 references indexed in Scilit:
- Critical research gaps and translational priorities for the successful prevention and treatment of breast cancerBreast Cancer Research, 2013
- Tim-3 Expression in Cervical Cancer Promotes Tumor MetastasisPLOS ONE, 2013
- IL-12 upregulates TIM-3 expression and induces T cell exhaustion in patients with follicular B cell non-Hodgkin lymphomaJournal of Clinical Investigation, 2012
- TIM-3 Expression Characterizes Regulatory T Cells in Tumor Tissues and Is Associated with Lung Cancer ProgressionPLOS ONE, 2012
- Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemiaBlood, 2011
- Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunityJournal of Experimental Medicine, 2010
- Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen–specific CD8+ T cell dysfunction in melanoma patientsJournal of Experimental Medicine, 2010
- Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008International Journal of Cancer, 2010
- TIM‐3 is expressed on activated human CD4+ T cells and regulates Th1 and Th17 cytokinesEuropean Journal of Immunology, 2009
- TIM-1 and TIM-3 enhancement of Th2 cytokine production by mast cellsBlood, 2007